Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 78.56 B
The data is delayed by 15 minutes.
Description: Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company?s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company?s
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||774.6 M||EPS||3.09||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||14.91%||Sales Growth - Q/Q||9.47%||P/E||39.6|
|P/E To EPS Growth||P/S||9.32||P/BV||12.43||Price/Cash Per Share||10.49|
|Price/Free Cash Flow||29.58||ROA||12.38%||ROE||34.76%||ROI||15.22%|
|Current Ratio||3.34||Quick Ratio||3.2||Long Term Debt/Equity||0.9||Debt Ratio||0.47|
|Gross Margin||95.19%||Operating Margin||31.72%||Net Profit Margin||26.08%||Dividend Payout Ratio|
|Cash From Financing Activities||-951.3 M||Cash From Investing Activities||239.7 M||Cash From Operating Activities||1.14 B||Gross Profit||2.18 B|
|Net Profit||356.2 M||Operating Profit||412.4 M||Total Assets||17.75 B||Total Current Assets||9.88 B|
|Total Current Liabilities||2.96 B||Total Debt||7.62 B||Total Liabilities||11.42 B||Total Revenue||2.28 B|
|High 52 week||100.95||Low 52 week||59.21||Last close||100.95||Last change||0.56%|
|RSI||64.77||Average true range||1.09||Beta||1.07||Volume||2.51 M|
|Simple moving average 20 days||1.69%||Simple moving average 50 days||3.66%||Simple moving average 200 days||8.8%|
|Performance Week||2.09%||Performance Month||2.61%||Performance Quart||11.09%||Performance Half||6.77%|
|Performance Year||22.25%||Performance Year-to-date||57.51%||Volatility daily||0.65%||Volatility weekly||1.44%|
|Volatility monthly||2.96%||Volatility yearly||10.25%||Relative Volume||218.43%||Average Volume||3.53 M|
|New High||New Low|
2020-05-27 10:00:53 | Is Amgen Stock A Buy As It Takes A Two-Pronged Approach To Coronavirus?
2020-05-27 08:00:05 | The No. 1 Pharma Is Poised For Double-Digit Growth — Is BMY Stock A Buy?
2020-05-19 08:00:53 | Biotech Giant Amgen Is Nearing A Breakout, But Is AMGN Stock A Buy?
2020-05-07 04:46:25 | Stocks - Peloton, PayPal Surge in Premarket on Boost From Lockdowns
2020-05-01 08:00:53 | Biotech Amgen Is Tackling Coronavirus From Two Sides — But Is It A Buy?
2020-04-22 08:00:05 | Is The No. 1 Pharmaceutical Stock A Buy As It Approaches A Breakout?
2020-03-26 13:02:05 | The No. 1 Pharma Company Nabbed A Key Approval — But Is It A Buy?
2020-03-13 16:22:11 | Celgene Corporation -- Moody's withdraws Celgene's ratings
2020-03-12 09:00:05 | Is The No. 1 Pharma Stock A Buy Following Its Massive Acquisition?
2020-03-05 08:00:05 | The No. 1 Pharma Stock Just Topped A Buy Point — Is BMY Stock A Buy?
2020-02-28 10:33:39 | GAMCO Investors Exits Viacom, Spark Therapeutics
2020-02-26 14:22:32 | Ronald Muhlenkamp's Firm Exits Celgene, Trims Gilead Position
2020-02-26 09:00:05 | Bristol-Myers Stock Retains Its Breakout — Is It Time To Add Shares?
2020-02-25 11:26:49 | Pioneer Investments Cuts Linde, McDonald's
2020-02-21 12:13:26 | Ronald Muhlenkamp's Firm Buys 3 Stocks in 4th Quarter
2020-02-20 12:37:50 | David Abrams Buys 2 Stocks in 4th Quarter
2020-02-19 12:09:47 | David Rolfe's Firm Cuts Apple, Visa
2020-02-07 08:00:05 | Bristol-Myers Posts Bullish Growth — But Is It Time To Add BMY Stock?
2020-02-04 14:32:23 | Eaton Vance Exits Celgene, Trims Amgen Position
2020-01-28 05:26:18 | Acceleron stock soars on lung drug trial data
2019-12-30 10:35:59 | An Unusual Investment With 125% Upside
2019-12-16 07:30:10 | NexImmune Appoints Sol Barer as Chairman of the Board of Directors
2019-12-12 13:06:10 | Bristol-Myers business development head Biondi departs
2019-12-10 10:10:03 | Biotech ETFs Hit New Highs on Deal Activities
2019-12-09 09:02:00 | Bristol-Myers Jumps After Celgene-Acquired Cancer Treatment Shows Promise
2019-12-07 14:00:00 | Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal
2019-12-06 16:30:40 | Bluebird, Celgene Cancer Therapy Gets Boost From New Study
2019-12-06 15:30:12 | Bristol-Myers Squibb Company -- Moody's upgrades Celgene to A3
2019-12-04 08:00:05 | Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?
2019-12-03 17:09:10 | $50M deal could expand NanoString Technologies diagnostic test into more markets
2019-11-26 03:09:00 | Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead
2019-11-24 22:32:29 | Here is the 17th Most Popular Stock Among 752 Hedge Funds
2019-11-24 16:19:59 | The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More
2019-11-22 09:00:05 | Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?
2019-11-21 17:58:10 | Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal
2019-11-21 17:20:00 | Bristol-Myers’ Binary Bet on Celgene Drugs Makes a Splash in Debut
2019-11-21 16:28:35 | Amgen Wraps Otezla Takeover — And Other Fallout From BMY's Celgene Buy
2019-11-21 09:40:02 | Biotech ETF BBH Hits New 52-Week High
2019-11-21 06:41:02 | Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug
2019-11-21 06:21:00 | Amgen Completes Acquisition Of Otezla® apremilast
2019-11-21 04:37:00 | Bristol-Myers Closes $74 Billion Celgene Takeover; Shares Gain
2019-11-20 16:45:00 | An All or Nothing Bet on 3 Drugs in Celgene’s Pipeline
2019-11-20 16:36:00 | Bristol-Myers Squibb completes $74 billion acquisition of Celgene
2019-11-20 16:33:00 | At Long Last, Bristol-Myers Buys Celgene
2019-11-20 09:40:02 | Top Ranked Growth Stocks to Buy for November 20th
2019-11-20 09:31:02 | Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More